CTNM
NASDAQ · Pharmaceuticals
Contineum Therapeutics Inc-A
$12.21
+0.10 (+0.83%)
Financial Highlights (FY 2025)
Revenue
273.32M
Net Income
33.71M
Gross Margin
31.2%
Profit Margin
12.3%
Rev Growth
-0.8%
D/E Ratio
0.64
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 31.2% | 31.2% | 31.2% |
| Operating Margin | 12.5% | 11.5% | 12.0% |
| Profit Margin | 12.3% | 10.4% | 10.0% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 273.32M | 248.64M | 220.16M |
| Gross Profit | 85.23M | 77.54M | 68.65M |
| Operating Income | 34.21M | 28.66M | 26.51M |
| Net Income | 33.71M | 25.85M | 22.01M |
| Gross Margin | 31.2% | 31.2% | 31.2% |
| Operating Margin | 12.5% | 11.5% | 12.0% |
| Profit Margin | 12.3% | 10.4% | 10.0% |
| Rev Growth | -0.8% | +22.0% | +2.7% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 170.90M | 168.09M | 146.24M |
| Total Equity | 266.33M | 244.64M | 253.88M |
| D/E Ratio | 0.64 | 0.69 | 0.58 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 45.63M | 48.42M | 37.59M |
| Free Cash Flow | 26.06M | 26.05M | 25.67M |